Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RAB9A | P51151 | 3/20 | 0.59 |
| ▸ | MEN1 | O00255 | 2/20 | 0.59 |
| ▸ | NPC1 | O15118 | 2/20 | 0.59 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.59 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.59 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.59 |
| ▸ | LMNA | P02545 | 1/20 | 0.59 |
| ▸ | MAPT | P10636 | 1/20 | 0.59 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.59 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.59 |
| ▸ | NHERF1 | O14745 | 1/20 | 0.56 |
| ▸ | F7 | P08709 | 2/20 | 0.55 |
| ▸ | F3 | P13726 | 2/20 | 0.55 |
| ▸ | FFAR1 | O14842 | 10/20 | 0.50 |
| ▸ | PPARG | P37231 | 2/20 | 0.50 |
| ▸ | GRIK1 | P39086 | 1/20 | 0.44 |
| ▸ | DAO | P14920 | 1/20 | 0.44 |
| ▸ | TP53 | P04637 | 1/20 | 0.44 |
| ▸ | SIRT1 | Q96EB6 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6439902 | 0.84 | F2 (0.49) | RAB9AALDH1A1KDM4ENHERF1F7 | |
| SCHEMBL27437769 | 0.83 | KDR (0.56) | RAB9AMEN1NPC1KMT2AALDH1A1 | |
| SCHEMBL25175575 | 0.80 | KDM4E (0.62) | RAB9AMEN1NPC1KMT2AALDH1A1 | |
| SCHEMBL28167722 | 0.79 | MEN1 (0.61) | RAB9AMEN1NPC1KMT2AALDH1A1 | |
| SCHEMBL11488198 | 0.79 | MEN1 (0.61) | RAB9AMEN1NPC1KMT2AALDH1A1 | |
| SCHEMBL17065800 | 0.77 | MEN1 (0.63) | RAB9AMEN1NPC1KMT2AALDH1A1 | |
| SCHEMBL26086683 | 0.76 | F3 (0.50) | RAB9AKDM4EF3DAO | |
| SCHEMBL28763445 | 0.76 | MEN1 (0.61) | RAB9AMEN1NPC1KMT2AALDH1A1 | |
| SCHEMBL29808535 | 0.75 | KDM4E (0.70) | RAB9AMEN1NPC1KMT2AALDH1A1 | |
| SCHEMBL6117859 | 0.75 | MEN1 (1.00) | RAB9AMEN1NPC1KMT2AALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8598355-B2 | Amide compound | ASTELLAS PHARMA INC. (JP) | 2013-12-03 | — | — | US | disclosed |
| EP-2565191-A1 | 4-(Indol-7-ylcarbonylaminomethyl)cyclohexanecarboxylic acid derivatives as EP4 receptor antagonists useful for the treatment of chronic renal failure or diabetic nephropathy | Astellas Pharma Inc. (JP) | 2013-03-06 | — | — | EP | disclosed |
| US-20110144153-A1 | AMIDE COMPOUND | ASTELLAS PHARMA INC. (JP) | 2011-06-16 | — | — | US | disclosed |
| US-20110144153-A1 | AMIDE COMPOUND | ASTELLAS PHARMA INC. (JP) | 2011-06-16 | — | — | US | disclosed |
| US-20110144153-A1 | AMIDE COMPOUND | ASTELLAS PHARMA INC. (JP) | 2011-06-16 | — | — | US | disclosed |
| CN-102026961-A | Amide compound | ASTELLAS PHARMA INC | 2011-04-20 | — | — | CN | disclosed |
| EP-2277858-A1 | AMIDE COMPOUND | Astellas Pharma Inc. (JP) | 2011-01-26 | — | — | EP | disclosed |
| EP-2277858-A1 | AMIDE COMPOUND | Astellas Pharma Inc. (JP) | 2011-01-26 | — | — | EP | disclosed |
| WO-2009139373-A1 | AMIDE COMPOUND | アステラス製薬株式会社 (JP) | 2009-11-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110144153-A1 | AMIDE COMPOUND | PTGER4, PTGER1, PTGER2 | RAB9A 3160/4885MEN1 4408/4885NPC1 2978/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.